CN1077885C - 联苯基磺酰胺基质金属蛋白酶抑制剂 - Google Patents

联苯基磺酰胺基质金属蛋白酶抑制剂 Download PDF

Info

Publication number
CN1077885C
CN1077885C CN97194719A CN97194719A CN1077885C CN 1077885 C CN1077885 C CN 1077885C CN 97194719 A CN97194719 A CN 97194719A CN 97194719 A CN97194719 A CN 97194719A CN 1077885 C CN1077885 C CN 1077885C
Authority
CN
China
Prior art keywords
compound
alkyl
sulfonylamino
acid
methylbutanoic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN97194719A
Other languages
English (en)
Chinese (zh)
Other versions
CN1219166A (zh
Inventor
P·M·奥伯里恩
D·R·斯里斯科威克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of CN1219166A publication Critical patent/CN1219166A/zh
Application granted granted Critical
Publication of CN1077885C publication Critical patent/CN1077885C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/42—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
CN97194719A 1996-05-17 1997-04-24 联苯基磺酰胺基质金属蛋白酶抑制剂 Expired - Fee Related CN1077885C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1746096P 1996-05-17 1996-05-17
US60/017,460 1996-05-17

Publications (2)

Publication Number Publication Date
CN1219166A CN1219166A (zh) 1999-06-09
CN1077885C true CN1077885C (zh) 2002-01-16

Family

ID=21782716

Family Applications (1)

Application Number Title Priority Date Filing Date
CN97194719A Expired - Fee Related CN1077885C (zh) 1996-05-17 1997-04-24 联苯基磺酰胺基质金属蛋白酶抑制剂

Country Status (22)

Country Link
EP (1) EP0901466B1 (enExample)
JP (1) JP2000511175A (enExample)
KR (1) KR20000011095A (enExample)
CN (1) CN1077885C (enExample)
AT (1) ATE207891T1 (enExample)
BG (1) BG63940B1 (enExample)
BR (1) BR9710841A (enExample)
CA (1) CA2253342A1 (enExample)
CZ (1) CZ294063B6 (enExample)
DE (1) DE69707865T2 (enExample)
DK (1) DK0901466T3 (enExample)
EA (1) EA001561B1 (enExample)
EE (1) EE03965B1 (enExample)
ES (1) ES2167733T3 (enExample)
IL (1) IL126832A0 (enExample)
NO (1) NO312510B1 (enExample)
NZ (1) NZ332711A (enExample)
PL (1) PL186416B1 (enExample)
PT (1) PT901466E (enExample)
SK (1) SK282863B6 (enExample)
WO (1) WO1997044315A1 (enExample)
ZA (1) ZA974223B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU690703B2 (en) * 1994-06-22 1998-04-30 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US6124333A (en) * 1995-06-22 2000-09-26 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
MXPA99001974A (es) * 1996-12-09 2002-03-27 Warner Lambert Co Metodo para tratar y prevenir fallas cardiacas y dilatacion ventricular.
EP1366765A1 (en) * 1996-12-17 2003-12-03 Warner-Lambert Company Llc Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
BR9714142A (pt) * 1996-12-17 2000-02-29 Warner Lambert Co Uso de inibidores de metaloproteìnases matriciais para tratamento de distúrbios neurológicos e promoção de cicatrização de feridas
GB9706255D0 (en) * 1997-03-26 1997-05-14 Smithkline Beecham Plc Novel compounds
DE19719621A1 (de) * 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren
ID24105A (id) 1997-07-22 2000-07-06 Shionogi & Co Komposisi untuk mengobati atau mencegah glomerulopati
BR9814422A (pt) * 1997-12-23 2000-10-10 Warner Lambert Co Combinações de inibidor de ace - inibidor de mmp
PL342009A1 (en) * 1998-02-04 2001-05-07 Novartis Ag Sulphonylamine derivatives capable to inhibit extracellular substance degrading metaloproteinases
US6410580B1 (en) 1998-02-04 2002-06-25 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
JP2002506818A (ja) * 1998-03-17 2002-03-05 ワーナー−ランバート・カンパニー スタチン−マトリックスメタロプロテイナーゼ阻害剤組み合わせ物
EP0967201A1 (en) * 1998-05-20 1999-12-29 Roche Diagnostics GmbH Pharmaceutical agents containing sulfonamids as matrix metalloproteinase inhibitors
EP1097159B1 (de) 1998-07-16 2002-11-06 Aventis Pharma Deutschland GmbH Phosphin- und phosphonsäurederivate als arzneimittel
OA11584A (en) * 1998-07-21 2004-07-20 Warner Lambert Co Coadministration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions.
DE19851184A1 (de) 1998-11-06 2000-05-11 Aventis Pharma Gmbh N-Arylsulfonyl-aminosäure-omega-amide
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
PL351374A1 (en) * 1999-04-19 2003-04-07 Shionogi & Co Sulfonamide derivatives having oxadiazole rings
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
WO2001037826A1 (en) 1999-11-26 2001-05-31 Shionogi & Co., Ltd. Npyy5 antagonists
EP1331224A4 (en) * 2000-09-29 2004-03-17 Shionogi & Co THIAZOLE AND OXAZOLE DERIVATIVES
GB0103303D0 (en) 2001-02-09 2001-03-28 Novartis Ag Organic compounds
MXPA01013326A (es) 2001-02-14 2002-08-26 Warner Lambert Co Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz.
WO2003035610A1 (en) * 2001-10-26 2003-05-01 Shionogi & Co., Ltd. Sulfonamide derivative having mmp inhibitory activity
GB0314488D0 (en) * 2003-06-20 2003-07-23 Glaxo Group Ltd Therapeutically useful compounds
BR0318625A (pt) 2003-12-04 2006-10-31 Wyeth Corp biaril sulfonamidas e métodos para usar as mesmas
CN101001834B (zh) * 2004-03-22 2011-06-29 南方研究院 基质金属蛋白酶的非肽抑制剂
CN101279956B (zh) * 2008-04-25 2011-06-15 南昌大学 一种基质金属蛋白酶抑制剂及合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995035276A1 (en) * 1994-06-22 1995-12-28 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
WO1996000214A1 (en) * 1994-06-24 1996-01-04 Ciba-Geigy Ag Arylsulfonamido-substituted hydroxamic acids as matrix metalloproteinase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995035276A1 (en) * 1994-06-22 1995-12-28 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
WO1996000214A1 (en) * 1994-06-24 1996-01-04 Ciba-Geigy Ag Arylsulfonamido-substituted hydroxamic acids as matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
PL186416B1 (pl) 2004-01-30
CA2253342A1 (en) 1997-11-27
PT901466E (pt) 2002-04-29
EP0901466A1 (en) 1999-03-17
NO312510B1 (no) 2002-05-21
ZA974223B (en) 1997-12-10
KR20000011095A (ko) 2000-02-25
SK157798A3 (en) 1999-04-13
AU713286B2 (en) 1999-11-25
ES2167733T3 (es) 2002-05-16
JP2000511175A (ja) 2000-08-29
NZ332711A (en) 2000-06-23
EP0901466B1 (en) 2001-10-31
CN1219166A (zh) 1999-06-09
HK1019585A1 (en) 2000-02-18
WO1997044315A1 (en) 1997-11-27
SK282863B6 (sk) 2002-12-03
PL329929A1 (en) 1999-04-26
CZ294063B6 (cs) 2004-09-15
DE69707865D1 (de) 2001-12-06
ATE207891T1 (de) 2001-11-15
CZ366898A3 (cs) 1999-02-17
EA001561B1 (ru) 2001-04-23
IL126832A0 (en) 1999-08-17
AU2680397A (en) 1997-12-09
BR9710841A (pt) 1999-08-17
BG63940B1 (bg) 2003-07-31
EE03965B1 (et) 2003-02-17
EA199800988A1 (ru) 1999-04-29
DK0901466T3 (da) 2002-02-18
NO985326L (no) 1999-01-14
NO985326D0 (no) 1998-11-16
EE9800397A (et) 1999-06-15
BG102918A (en) 1999-09-30
DE69707865T2 (de) 2002-05-02

Similar Documents

Publication Publication Date Title
CN1219166A (zh) 联苯基磺酰胺基质金属蛋白酶抑制剂
CN1196671C (zh) 单和双取代的3－丙基－γ－氨基丁酸
CN1279673A (zh) (环)烷基取代的)－γ－氨基丁酸衍生物(=GABA类似物),其制备和在治疗神经病中的用途
CN1230177A (zh) 作为基质金属蛋白酶抑制剂的β－磺酰基异羟肟酸
CN1551866A (zh) 羧酸衍生物化合物及包含这些化合物为活性成分的药物
CN1812963A (zh) 用于治疗阿尔茨海默病的N－烷基苯基甲酰胺β分泌酶抑制剂
CN1198096A (zh) 用于治疗与胶原蛋白过量产生有关的疾病的c－蛋白酶抑制剂
CN1140508C (zh) 作为基质金属蛋白酶抑制剂的取代4-联苯基-4-羟基丁酸衍生物
CN1090282A (zh) 苯稠合羟基取代的环烷基和杂环化合物的磺酰胺衍生物
CN1206213C (zh) N－芳基磺酰氨基酸ω－酰胺
CN1033800A (zh) 茚满衍生物和其制备方法
CN1051354A (zh) 取代环烷并[b]二氢吲哚-和-吲哚磺酰胺
CN1419549A (zh) 不对称的4,6－双(芳氧基)嘧啶衍生物的制备方法
CN1212835C (zh) 含异羟肟酸酯的半胱氨酸和丝氨酸蛋白酶抑制剂
CN1125815C (zh) 用于合成喹啉衍生物的方法
CN1087295C (zh) 环氧琥珀酸衍生物
CN1097007A (zh) 制备2-亚氨基噻唑啉衍生物的方法和制备其中间产物的方法
CN1097745A (zh) 取代的哌嗪
CN87107427A (zh) 取代的氨甲基-5，6，7，8-四氢萘氧代乙酸，新的中间体产物，它们的制备过程及其作为药物的应用
CN1163472C (zh) 用于制备手性氨基酸的新方法
CN1062525A (zh) 苯基烷氨基化合物及其制造方法以及含这些化合物的药剂
CN1551871A (zh) 制备噻唑ppar-配体及其多晶型物的方法
CN1107137A (zh) 显示磷脂酶a2抑制活性的新的羧酸酯衍生物
HK1019585B (en) Biphenylsulfonamide matrix metalloproteinase inhibitors
CN1225622A (zh) 作为基质金属蛋白酶抑制剂的取代的氧代丁酸衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee